» Articles » PMID: 30681834

Rational Design of Cancer Nanomedicine for Simultaneous Stealth Surface and Enhanced Cellular Uptake

Overview
Journal ACS Nano
Specialty Biotechnology
Date 2019 Jan 26
PMID 30681834
Citations 48
Authors
Affiliations
Soon will be listed here.
Abstract

Owing to the complex and still not fully understood physiological environment, the development of traditional nanosized drug delivery systems is very challenging for precision cancer therapy. It is very difficult to control the in vivo distribution of nanoparticles after intravenous injection. The ideal drug nanocarriers should not only have stealth surface for prolonged circulation time but also possess enhanced cellular internalization in tumor sites. Unfortunately, the stealth surface and enhanced cellular uptake seem contradictory to each other. How to integrate the two opposite aspects into one system is a very herculean but meaningful task. As an alternative drug delivery strategy, chameleon-like drug delivery systems were developed to achieve long circulation time while maintaining enhanced cancer cell uptake. Such drug nanocarriers can "turn off" their internalization ability during circulation. However, the enhanced cellular uptake can be readily activated upon arriving at tumor tissues. In this way, stealth surface and enhanced uptake are of dialectical unity in drug delivery. In this review, we focus on the surface engineering of drug nanocarriers to obtain simultaneous stealth surfaces in circulation and enhanced uptake in tumors. The current strategies and ongoing developments, including programmed tumor-targeting strategies and some specific zwitterionic surfaces, will be discussed in detail.

Citing Articles

Engineered bacterial membrane biomimetic covalent organic framework as nano-immunopotentiator for cancer immunotherapy.

Yang Q, Wang Y, Wang S, Song A, Wang W, Zhang L Bioact Mater. 2025; 47:283-294.

PMID: 39925708 PMC: 11803166. DOI: 10.1016/j.bioactmat.2025.01.018.


Brain-targeting drug delivery systems: The state of the art in treatment of glioblastoma.

Sun B, Li R, Ji N, Liu H, Wang H, Chen C Mater Today Bio. 2025; 30:101443.

PMID: 39866779 PMC: 11759563. DOI: 10.1016/j.mtbio.2025.101443.


Emerging advances in drug delivery systems (DDSs) for optimizing cancer complications.

Li K, Guo B, Gu J, Ta N, Gu J, Yu H Mater Today Bio. 2025; 30:101375.

PMID: 39759851 PMC: 11699619. DOI: 10.1016/j.mtbio.2024.101375.


Progress in Nanotechnology for Treating Ocular Surface Chemical Injuries: Reflecting on Advances in Ophthalmology.

Qi Q, Su D, Zhuang S, Yao S, Heindl L, Fan X Adv Sci (Weinh). 2025; 12(6):e2407340.

PMID: 39755928 PMC: 11809354. DOI: 10.1002/advs.202407340.


Matrix metalloproteinase 2-responsive dual-drug-loaded self-assembling peptides suppress tumor growth and enhance breast cancer therapy.

Ma J, Yang H, Tian X, Meng F, Zhai X, Li A Bioeng Transl Med. 2024; 9(6):e10702.

PMID: 39545088 PMC: 11558207. DOI: 10.1002/btm2.10702.